A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer

European Journal of Cancer

Volumn 67, Issue , 2016, Pages 11-20

  Heinemann, Volker ^a   Rivera, Fernando ^b   O'Neil, Bert H ^c   Stintzing, Sebastian ^a   Koukakis, Reija ^d   Terwey, Jan Henrik ^e   Douillard, Jean Yves ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AMGEN LTD   (United Kingdom)

^e AMGEN INC   (United States)

^f UMR INSERM U892 CNRS 6299   (France)

Author keywords

Bevacizumab; Cetuximab; Meta analysis; Panitumumab; Progression free survival; Survival

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PANITUMUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MAGNESIUM; MONOCLONAL ANTIBODY; RAS PROTEIN;

ACNE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EXON; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; MEDLINE; META ANALYSIS; METASTATIC COLORECTAL CANCER; NAUSEA; NEUROPATHY; ONCOGENE K RAS; OVERALL SURVIVAL; PAIN; PARONYCHIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SKIN MANIFESTATION; SKIN TOXICITY; TREATMENT RESPONSE; WILD TYPE; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ERUPTIONS; GENETICS; METABOLIC DISORDER; PATHOLOGY; SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; HUMANS; MAGNESIUM; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; WATER-ELECTROLYTE IMBALANCE;

EID: 84984848472     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.07.019     Document Type: Article

References (35)

1. ®). Colon Cancer Version, 1, 2015.
2. [2] Schmoll, H.J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23 (2012), 2479–2516.
3. [3] Kirstein, M.M., Lange, A., Prenzler, A., Manns, M.P., Kubicka, S., Vogel, A., Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist 19 (2014), 1156–1168.
4. [4] Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004), 229–237.
5. [5] Lenz, H.J., Lee, F.C., Yau, L., Koh, H.A., Knost, J.A., Mitchell, E.P., et al. MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol, 34(Suppl. 4S), 2016 Abstract 493.
6. [6] Abad, A., Massuti, B., Grávalos, C., Escudero, P., Guillén-Ponce, C., Manzano, J.L., et al. Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: the PLANET study. J Clin Oncol, 32(Suppl.), 2014 Abstract 3560.
7. [7] Yamazaki, K., Nagase, M., Tamagawa, H., Ueda, S., Tamura, T., Murata, K., et al. A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G). J Clin Oncol, 32(Suppl. 5S), 2014 Abstract 3534.
8. ® (panitumumab) summary of product characteristics. 2015.
9. ® (cetuximab) summary of product characteristics. 2015.
10. [10] Price, T.J., Bruhn, M.A., Lee, C.K., Hardingham, J.E., Townsend, A.R., Mann, K.P., et al. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer 112 (2015), 963–970.
11. [11] Koike, J., Ushigome, M., Funahashi, K., Shiokawa, H., Kaneko, T., Arai, K., et al. Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer. Hepatogastroenterology 61 (2014), 2222–2226.
12. ® (bevacizumab) summary of product characteristics. 2015.
13. [13] Venook, A.P., Niedzwiecki, D., Lenz, H.J., Innocenti, F., Mahoney, M.R., O'Neil, B.H., et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the rectum or colon (MCRC). J Clin Oncol, 32(Suppl. 5S), 2014 Abstract LBA3.
14. [14] Heinemann, V., von Weikersthal, L.F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.E., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15 (2014), 1065–1075.
15. [15] Lenz, H., Niedzwiecki, D., Innocenti, F., Blanke, C., Mahoney, M.R., O'Neil, B.H., et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol, 25(Suppl. 4), 2014 Abstract 501O.
16. [16] Heinemann, V., Modest, D.P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., et al. Independent radiological evaluation of objective response, early tumour shrinkage, and depth of response in FIRE-3 (AIO KRK-0306). Ann Oncol, 25(Suppl. 4), 2014 Abstract O-0030.
17. [17] Schwartzberg, L.S., Rivera, F., Karthaus, M., Fasola, G., Canon, J.L., Hecht, J.R., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32 (2014), 2240–2247.
18. [18] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
19. [19] Stintzing, S., Jung, A., Rossius, L., Modest, D.P., Fischer von Weikersthal, L., Decker, T., et al. Mutations within the EGFR signaling pathway: influences on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol, 32(Suppl. 3), 2014 Abstract 445.
20. [20] Rivera, F., Karthaus, M., Hecht, J.R., Fasola, G., Canon, J.L., Guan, X., et al. Final analysis of the PEAK trial: overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC). Eur J Cancer, 51(Suppl), 2015 Abstract 2014.
21. [21] Modest, D.P., Stintzing, S., von Weikersthal, L.F., Decker, T., Kiani, A., Vehling-Kaiser, U., et al. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol 33 (2015), 3718–3726.
22. [22] Sorich, M.J., Wiese, M.D., Rowland, A., Kichenadasse, G., McKinnon, R.A., Karapetis, C.S., Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26 (2015), 13–21.
23. [23] Khattak, M.A., Martin, H., Davidson, A., Phillips, M., Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer 14 (2015), 81–90.
24. [24] Giessen, C., Laubender, R.P., Fischer von, W.L., Schalhorn, A., Modest, D.P., Stintzing, S., et al. Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial. Cancer Sci 104 (2013), 718–724.
25. [25] Douillard, J.Y., Siena, S., Peeters, M., Koukakis, R., Terwey, J.H., Tabernero, J., Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 51 (2015), 1231–1242.
26. [26] Cremolini, C., Loupakis, F., Antoniotti, C., Lonardi, S., Masi, G., Salvatore, L., et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26 (2015), 1188–1194.
27. [27] Heinemann, V., Stintzing, S., Modest, D.P., Giessen-Jung, C., Michl, M., Mansmann, U.R., Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 51 (2015), 1927–1936.
28. [28] Petrelli, F., Pietrantonio, F., Cremolini, C., Di Bartolomeo, M., Coinu, A., Lonati, V., et al. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. Eur J Cancer 51 (2015), 800–807.
29. [29] Stintzing, S., Modest, D.P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population. Ann Oncol, 25(Suppl 4), 2014 Abstract LBA11.
30. [30] Rivera, F., Karthaus, M., Hecht, J.R., Fasola, G., Canon, J.L., Koukakis, R., et al. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): tumor response outcomes beyond RECIST. J Clin Oncol, 33(Suppl 3), 2015 Abstract 660.
31. [31] Douillard, J.Y., Oliner, K.S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034.
32. [32] Van Cutsem, E., Lenz, H.J., Köhne, C.H., Heinemann, V., Tejpar, S., Melezinek, I., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33 (2015), 692–700.
33. [33] Yoshino, T., Uetake, H., Tsuchihara, K., Shitara, K., Yamazaki, K., Oki, E., et al. PARADIGM study: a multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS(KRAS/NRAS) wild-type metastatic colorectal cancer. J Clin Oncol, 34(Suppl 4S), 2016 Abstract TPS776.
34. [34] Wainberg, Z.A., Drakaki, A., The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. Expert Opin Biol Ther 15 (2015), 1205–1220.
35. [35] Price, T.J., Peeters, M., Kim, T.W., Li, J., Cascinu, S., Ruff, P., et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15 (2014), 569–579.